CTLA4 and neoplasm: Moreover, PD-1 blockade predominantly activates T cells within the tumor, whereas anti-CTLA-4 may activate T cells primarily in the lymph nodes46, in which high levels of anti-CTLA-4 can be achieved by IT delivery.